Showing Results for
- Academic Journals (677)
Search Results
- 677
Academic Journals
- 677
-
From:Indian Journal of Medical and Paediatric Oncology (Vol. 34, Issue 4) Peer-ReviewedByline: Waseem. Raja, M. Mir, Imtiyaz. Dar, Muzamil. Banday, Irfan. Ahmad Cisplatin or cis-diamminedichloroplatinum (CDDP) is the first member of a class of platinum-containing anti-cancer drugs that act by binding...
-
From:Pharmacogenomics (Vol. 15, Issue 13) Peer-ReviewedAuthor(s): Timothy F Spracklen aff1 , Heather Whitehorn aff1 , Anna Alvera Vorster aff1 , Lebogang Ramma aff2 , Sameera Dalvie aff3 , Rajkumar S Ramesar [*] aff1 Keywords: cisplatin; hearing loss; Otos ;...
-
From:Phytomedicine: International Journal of Phytotherapy & Phytopharmacology (Vol. 22, Issue 6) Peer-ReviewedABSTRACT Background: Oral mucositis is a common adverse effect of antineoplastic chemotherapy limiting sufficient dose of chemoregimen. Numerous attempts to mitigate chemotherapy-induced oral mucositis have failed to...
-
From:Reactions Weekly (Issue 1336)[S] A 50-year-old man developed arterial occlusion leading to gangrene of the toe during cisplatin-based chemotherapy for testicular cancer. The man, who was a chronic smoker, began an etoposide-cisplatin...
-
From:Pharmacogenomics (Vol. 13, Issue 13) Peer-ReviewedAuthor(s): Godefridus J Peters [*] 2 , Elisa Giovannetti 1 Evaluation of: Han JY, Shin ES, Lee YS et al. A genome-wide association study for irinotecan-related severe toxicities in patients with advanced...
-
From:Reactions Weekly (Issue 1283)[X] [S] A 63-year-old man with hypertension and type 2 diabetes mellitus started treatment with cisplatin [dosage not stated] and gemcitabine for high-grade urethral cancer. He was also started on...
-
From:Abstracts in Hematology & Oncology (Vol. 10, Issue 4)Siu LL, Soulieres D, Chen EX, et al. J Clin Oncol. 2007;25:2178-2183. ABSTRACT This phase 2 study of patients with recurrent or metastatic squamous cell carcinoma of the head and neck enrolled patients who had no...
-
From:British Medical Journal (Vol. 311, Issue 7010) Peer-ReviewedChemotherapy may somewhat prolong survival among patients with non-small cell lung cancer, a cancer with low survival chances. Most lung cancers are of the non-small cell type. Researchers analyzed the effect of...
-
From:Journal of Experimental & Clinical Cancer Research (Vol. 28) Peer-ReviewedAuthors: Eva Henriksson (corresponding author) [1]; Elisabeth Kjellén [2]; Bo Baldetorp [2]; Pär-Ola Bendahl [2]; Åke Borg [2]; Eva Brun [2]; Fredrik Mertens [3]; Tomas Ohlsson [4]; Karin Rennstam [2]; Johan Wennerberg...
-
From:PLoS ONE (Vol. 9, Issue 2) Peer-ReviewedAuthor(s): Cristina Federici 1, Francesco Petrucci 2, Stefano Caimi 2, Albino Cesolini 3, Mariantonia Logozzi 1, Martina Borghi 1, Sonia D'Ilio 4, Luana Lugini 1, Nicola Violante 2, Tommaso Azzarito 1, Costanza Majorani...
-
From:European Journal of Clinical Nutrition (Vol. 70, Issue 6) Peer-ReviewedBACKGROUND/OBJECTIVES: Cancer cachexia is a syndrome characterized by weight loss (WL) and sarcopenia. Aim of the study was to assess the impact of cachexia on head and neck changes during definitive cisplatin and...
-
From:Oxidative Medicine and Cellular Longevity (Vol. 2017) Peer-ReviewedOur previous in vitro studies demonstrated that oxygen pretreatment significantly protects human embryonic renal tubular cell against acute cisplatin- (CP-) induced cytotoxicity. The present study was designed to...
-
From:Oxidative Medicine and Cellular Longevity (Vol. 2014) Peer-ReviewedBackground. The aim of this study is to investigate the protective effects of hemin (the heme oxygenase-1 [OH-1] inducer) against nephrotoxic effects induced by cisplatin [cis- diamminedichloroplatinum II (CP)] in male...
-
From:PLoS ONE (Vol. 7, Issue 10) Peer-ReviewedBackground It is a major clinical challenge to predict which patients, with advanced stage head and neck squamous cell carcinoma, will not exhibit a reduction in tumor size following induction chemotherapy in order...
-
From:PLoS ONE (Vol. 10, Issue 4) Peer-ReviewedCisplatin is one of the first-line platinum-based chemotherapeutic agents for treatment of many types of cancer, including ovary cancer. CTR1 (copper transporter 1), a transmembrane solute carrier transporter, has...
-
From:PLoS ONE (Vol. 6, Issue 2) Peer-ReviewedBackground We initiated a prospective trial to identify transcriptional alterations associated with acquired chemotherapy resistance from pre- and post-biopsy samples from the same patient and uncover potential...
-
From:PLoS ONE (Vol. 6, Issue 4) Peer-ReviewedCisplatin causes auditory impairment due to the apoptosis of auditory hair cells. There is no strategy to regulate ototoxicity by cisplatin thus far. Dansam-Eum (DSE) has been used for treating the central nerve system...
-
From:PLoS ONE (Vol. 7, Issue 12) Peer-ReviewedIntroduction Dexamethasone (DEX) co-treatment has proved beneficial in NSCLC patients, improving clinical symptoms by the reduction of side effects after chemotherapy. However, recent studies have shown that DEX...
-
From:PLoS ONE (Vol. 12, Issue 4) Peer-ReviewedPurpose The aim of this work was to investigate if the content of glutamyl aminopeptidase (GluAp) in microvesicular and exosomal fractions of urine is related with renal dysfunction in cisplatin-treated rats....
-
From:Journal of Biomedical Science (Vol. 24, Issue 1) Peer-ReviewedBackground The aldehyde dehydrogenase (ALDH) enzyme family metabolizes and detoxifies both exogenous and endogenous aldehydes. Since chemotherapeutic agents, such as cisplatin, generate cytotoxic aldehydes and...